Abstract
Background: Considerable evidence implicates CD40 signaling in the pathogenesis of atheromas. Exposure to CD40 ligand induces platelet-leukocyte conjugation, a heightened expression of inflammatory cytokines, matrix-degrading enzymes, and procoagulant factors. Objectives: To investigate the association between plasma soluble CD40 ligand (sCD40L) and platelet-monocyte aggregates in patients with obstructive sleep apnea (OSA) and to determine whether treatment of OSA with nasal continuous positive airway pressure (nCPAP) alters this relationship. Methods: Twelve patients with OSA who were free of other diseases and 12 healthy controls matched for age, gender, and body mass index had blood drawn for sCD40L and platelet-monocyte aggregate measurements. A repeat assessment was obtained following 8 weeks of nCPAP therapy. Results: Subjects with OSA had significantly higher plasma sCD40L levels and exhibited elevated platelet-monocyte aggregates compared to nonapneic subjects (7.6 ± 4.3 versus 1.7 ± 1.1, p = 0.004; and 41.3 ± 23.7 versus 6.7 ± 4.9, p = 0.001, respectively). Both parameters correlated positively with the percentage of time spent with SpO2 <90% (r = 0.69, p = 0.01 and r = 0.6, p = 0.03, respectively). After 8 weeks of nCPAP treatment, sCD40 levels declined by 47% (p = 0.003) and platelet-monocyte aggregates by 42% (p = 0.002). None of the controls showed any changes in either sCD40L or platelet- monocyte aggregates after nCPAP therapy. Conclusions: OSA is associated with upregulation of circulating sCD40L levels and platelet-monocyte aggregation that may account for the increased incidence of cardiovascular events in this population. Treatment with nCPAP may alleviate this risk.
Journal Section:
Editor's choice
References
1.
Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, O’Connor GT, Boland LL, Schwartz JE, Samet JM: Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:19–25.
2.
Shamsuzzaman AS, Gersh BJ, Somers VK: Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003;290:1906–1914.
3.
Oflaz H, Cuhadaroglu C, Pamukcu B, Meric M, Ece T, Kasikcioglu E, Koylan N: Endothelial function in patients with obstructive sleep apnea syndrome but without hypertension. Respiration 2006;73:751–756.
4.
Hatipoglu O, Rubinstein I: Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration 2003;70:665–671.
5.
El Solh AA, Akinnusi ME, Baddoura FH, Mankowski CR: Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med 2007;175:1186–1191.
6.
Bokinsky G, Miller M, Ault K, Husband P, Mitchell J: Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest 1995;108:625–630.
7.
Eisensehr I, Ehrenberg BL, Noachtar S, Korbett K, Byrne A, McAuley A, Palabrica T: Platelet activation, epinephrine, and blood pressure in obstructive sleep apnea syndrome. Neurology 1998;51:188–195.
8.
Geiser T, Buck F, Meyer BJ, Bassetti C, Haeberli A, Gugger M: In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002;69:229–234.
9.
Kobayashi K, Nishimura Y, Shimada T, Yoshimura S, Funada Y, Satouchi M, Yokoyama M: Effect of continuous positive airway pressure on soluble CD40 ligand in patients with obstructive sleep apnea syndrome. Chest 2006;129:632–637.
10.
Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, co-stimulation, and death. Cell 1994;76:959–962.
11.
Banchereau J, Bazan F, Blanchard D, Brière F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol 1994;12:881–922.
12.
Aukrust P, Wæhre T, Damås JK, Gullestad L, Solum NO: Inflammatory role of platelets in acute coronary syndromes. Heart 2001;86:605–606.
13.
Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD: Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003;90:377–384.
14.
Van Kooten C, Banchereau J: CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 1996;61:1–77.
15.
Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ: CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003;92:1041–1048.
16.
Harding SA, Sarma J, Josephs DH, Cruden NL, Din JN, Twomey PJ, Fox KA, Newby DE: Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 2004;109:1926–1929.
17.
Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE: CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 2005;25:2428–2434.
18.
Schönbeck U, Sukhova GK., Shimizu K, Mach F, Libby P: Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 2000;97:7458–7463.
19.
Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Davì G: Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002;106:399–402.
20.
van der Wal AC, Becker AE: Atherosclerotic plaque rupture – pathologic basis of plaque stability and instability. Cardiovasc Res 1999;41:334–344.
21.
Rechtschaffen A, Kales A (eds): A Manual of Standardized Terminology, Technique, and Scoring System for Sleep Stages of Human Subjects. Los Angeles, BIS/BRI, UCLA, 1968.
22.
Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540–545.
23.
Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG: Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001;104:2395–2400.
24.
Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernández-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, Schönbeck U: Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003;107:2664–2669.
25.
Schönbeck U, Varo N, Libby P, Buring J, Ridker PM: Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266–2268.
26.
Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Oda N, Tanaka A, Yamamoto M, Ohta S, O’Donnell CP, Adachi M: Silent brain infarction and platelet activation in obstructive sleep apnea. Am J Respir Crit Care Med 2007;175:612–617.
27.
Jennum P, Wildschiødtz G, Christensen NJ, Schwartz T: Blood pressure, catecholamines, and pancreatic polypeptide in obstructive sleep apnea with and without nasal Continuous Positive Airway Pressure (nCPAP) treatment. Am J Hypertens 1989;2:847–852.
28.
Dunleavy M, Dooley M, Cox D, Bradford A: Chronic intermittent asphyxia increases platelet reactivity in rats. Exp Physiol 2005;90:411–416.
29.
André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR: Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002;106:896–899.
30.
Kotowicz K, Dixon GL, Klein NJ, Peters MJ, Callard RE: Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology 2000;100:441–448.
31.
Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroszek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591–594.
32.
Viallard JF, Solanilla A, Gauthier B, Contin C, Déchanet J, Grosset C, Moreau JF, Praloran V, Nurden P, Pellegrin JL, Nurden AT, Ripoche J: Increased soluble and platelet- associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002;99:2612–2614.
33.
Jin Y, Nonoyama S, Morio T, Imai K, Ochs HD, Mizutani S: Characterization of soluble CD40 ligand released from human activated platelets. J Med Dent Sci 2001;48:23–27.
34.
Sarma J, Laan C, Alam S, Jha A, Fox KA, Dransfield I: Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2166–2171.
35.
von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C: RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001;103:1772–1777.
36.
Altieri DC, Morrissey JH, Edgington TS: Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA 1988;85:7462–7466.
37.
Zillmann A, Luther T, Müller I, Kotzsch M, Spannagl M, Kauke T, Oelschlägel U, Zahler S, Engelmann B: Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 2001;281:603–609.
38.
Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL 3rd, Goldberg RJ, Michelson AD: Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002–1006.
39.
Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61–67.
40.
Ahn ER, Lander G, Jy W, Bidot CJ, Jimenez JJ, Horstman LL, Ahn YS: Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 2004;114:143–148.
41.
Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK: Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 2002;105:2849–2854.
42.
Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL 3rd, Michelson AD: Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004;43:2319–2325.
© 2008 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2008
You do not currently have access to this content.
